Loading
institutionsInstitution
Peter MacCallum Cancer Centre
Peter Mac is Australia's only dedicated cancer hospital and a leader in theranostics, CAR-T, and radiation oncology.
Overview
Peter MacCallum Cancer Centre in Melbourne is Australia's only dedicated cancer hospital, the core of the Victorian Comprehensive Cancer Centre, and ranks fourteenth in the Newsweek/Statista oncology list. It pioneered PSMA PET imaging and lutetium-177 PSMA radioligand therapy through Hofman's TheraP and proPSMA trials, became Australia's first CAR-T centre, and has a strong radiation oncology programme, with Sarah-Jane Dawson, Joseph Trapani, Declan G. Murphy, Andrew H. Wei and Grant McArthur among its people. OnCo links it to prostate cancer, to the CROWN and DYNAMIC papers, to ANZUP and other Australian trial groups, and to ideas for a rapid research autopsy network and a shared cyclotron network for new tracers. Getting radioligand supply and regulation to match demand is the open problem its theranostics work exposes. Its trial and people pages carry the detail.
Location
Melbourne, AU
Type
cancer center
Website
Newsweek 2026 oncology rank
#14
OnCo score
#24 · 86 points (46 Newsweek + 0 NCI + 40 from 20 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-24.
Matched to Peter MacCallum Cancer Centre, including child institutions. 1,554 works · 24,520 citations · 69% open access · 17% clinical trials · 5% reviews.
Oncology works per year
3242022
3642023
3382024
3182025
2102026
Most works
- Michael Dickinson101 works
- Sherene Loi89 works
- Shahneen Sandhu66 works
- Michael Jefford64 works
- Alexander Graham Heriot62 works
- Roberto Salgado50 works
- Satish Kumar Warrier49 works
- Linda Mileshkin49 works
- Jayesh Desai45 works
- Benjamin Solomon42 works
Most cited
- PSMA theranostics (TheraP, proPSMA)
- CAR-T
- Radiation oncology
Andrew H. Wei
Consultant Haematologist, Peter MacCallum Cancer Centre and Royal Melbourne Hospital; Professor, University of Melbourne
Acute myeloid leukaemiaVenetoclaxMeasurable residual disease
Australian haematologist who led VIALE-C and QUAZAR AML-001, advancing venetoclax and oral azacitidine maintenance in AML.
Benjamin Solomon
Professor of Medical Oncology; Head, Lung Medical Oncology, Peter Mac
Lung cancerALK inhibitorsTargeted therapy
Principal investigator of CROWN, where lorlatinib produced the longest disease control ever recorded for a targeted lung cancer pill.
Danny Rischin
Medical oncologist and Director of Medical Oncology, Peter MacCallum Cancer Centre
Head and neck cancerCutaneous squamous-cell carcinomaChemoradiotherapy trials
Melbourne oncologist who led C-POST, the trial that showed cemiplimab after surgery and radiotherapy cuts recurrence in high-risk cutaneous squamous-cell carcinoma.
Declan G. Murphy
Director of Genitourinary Oncology, Peter MacCallum Cancer Centre
Urological surgeryPSMA PETRobotic prostatectomy
Urologist who co-led proPSMA, the trial that showed PSMA PET should replace CT and bone scan for staging prostate cancer.
Grant McArthur
Executive Director, Victorian Comprehensive Cancer Centre Alliance; melanoma medical oncologist, Peter Mac
MelanomaBRAF and MEK inhibitorsImmunotherapy
A melanoma pioneer who led the vemurafenib and cobimetinib trials and now heads Victoria's cancer alliance.
H. Miles Prince
Haematologist, Peter MacCallum Cancer Centre and Epworth Healthcare, Melbourne
Cutaneous T-cell lymphomaMultiple myelomaNovel agents in lymphoma
Melbourne haematologist who led ALCANZA, the trial that showed brentuximab vedotin beats standard treatment for CD30-expressing cutaneous T-cell lymphoma.
Jeanne Tie
Medical Oncologist, Peter MacCallum Cancer Centre; Laboratory Head, Walter and Eliza Hall Institute
Circulating tumour DNAColorectal cancerAdjuvant therapy
Led DYNAMIC, the first randomised trial to show ctDNA can safely guide who needs chemotherapy after colon cancer surgery.
John F. Seymour
Director of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital
Chronic lymphocytic leukaemiaVenetoclaxLymphoma
Led MURANO, which established venetoclax plus rituximab as fixed-duration therapy for relapsed CLL.
Joseph Trapani
Executive Director, Cancer Research, Peter Mac; immunologist
Cancer immunologyCytotoxic lymphocytesPerforin and granzymes
An immunologist who worked out how killer T cells destroy their targets, and now directs research at Australia's cancer hospital.
Linda Mileshkin
Medical Oncologist and Director of Clinical Trials, Peter MacCallum Cancer Centre
Cervical cancerGynaecologic oncologyCancer of unknown primary
Led OUTBACK, which showed adding chemotherapy after chemoradiation does not help cervical cancer, a key negative result.
Michael Dickinson
Lead, Aggressive Lymphoma Program, Peter MacCallum Cancer Centre and Royal Melbourne Hospital
Aggressive lymphomaBispecific antibodiesCAR T-cell therapy
Led the pivotal glofitamab trial, establishing off-the-shelf bispecific antibodies for relapsed large B-cell lymphoma.
Michael Hofman
Professor of Nuclear Medicine; Director, Prostate Cancer Theranostics and Imaging Centre of Excellence
TheranosticsPSMA PETLutetium-PSMA therapy
Led proPSMA and TheraP, the trials that proved PSMA PET beats conventional imaging and that lutetium-PSMA beats chemotherapy.
Prudence A. Francis
Head of Breast Medical Oncology, Peter MacCallum Cancer Centre
Premenopausal breast cancerOvarian function suppressionAdjuvant endocrine therapy
Led SOFT and TEXT, the trials that showed ovarian suppression plus exemestane helps young women with breast cancer.
Sarah-Jane Dawson
Professor; Head, Translational Genomics and Epigenomics Laboratory; medical oncologist, Peter Mac
Circulating tumour DNACancer genomicsBreast cancer
A ctDNA pioneer whose early work showed blood could track breast cancer better than protein markers or imaging.
Shahneen Sandhu
Medical oncologist; Lead, Genitourinary Oncology Theranostics, Peter Mac
Prostate cancerTheranosticsMelanoma
Runs the medical oncology side of Peter Mac's theranostics programme, combining lutetium-PSMA with hormonal and immune therapies.
Shankar Siva
Professor and Director of Radiation Oncology Research, Peter MacCallum Cancer Centre
Stereotactic radiotherapyKidney cancerOligometastatic disease
Radiation oncologist who established stereotactic radiotherapy as a non-surgical option for primary kidney cancer.
Sherene Loi
Professor and Head, Translational Breast Cancer Genomics and Therapeutics Laboratory; medical oncologist, Peter Mac
Breast cancerTumour-infiltrating lymphocytesImmunotherapy
Showed that immune cells inside breast tumours predict outcome, the basis for de-escalating chemotherapy in TNBC.
rctNew England Journal of Medicine 2022changed practice765 citations
DYNAMIC: a blood test safely halved chemotherapy use after surgery for stage II colon cancer
For stage II colon cancer, where most patients are cured by surgery alone, a blood test can identify the minority who benefit from chemotherapy and spare everyone else its side effects. It does not yet prove that treating ctDNA-positive patients improves survival compared with not treating them.
rctNew England Journal of Medicine 2020changed practice897 citations
First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer
The current first choice for ALK-positive lung cancer in most guidelines, and the strongest evidence in solid tumour oncology that a drug can be designed to work inside the brain. Five-year follow-up has since shown the majority of patients still progression-free.
translationalScience Translational Medicine 2016changed practice1,156 citations
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
Minimal residual disease became measurable in solid tumours, and the DYNAMIC and CIRCULATE trials that followed turned the measurement into a treatment decision.
Similar pages
- PersonUwe Haberkorn
Shares A university cyclotron network with shared regulatory files for new tracers, Lutetium-177 vipivotide tetraxetan, PSMA PET, Radioligand therapy (beta emitters).
- CollectionProstate Cancer Foundation (PCF)
Shares Movember, Lutetium-177 vipivotide tetraxetan, PSMA PET, Prostate cancer.
- PersonIan Davis
Shares proPSMA, ANZUP Cancer Trials Group, Prostate cancer.
- InstitutionTherapeutic Goods Administration
Shares Pharmaceutical Benefits Advisory Committee, ANZUP Cancer Trials Group, Radioligand therapy (beta emitters).
- PersonJohannes Czernin
Shares Lutetium-177 vipivotide tetraxetan, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
- PersonLouise Emmett
Shares Lutetium-177 vipivotide tetraxetan, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
- RoadmapRadiopharmaceutical roadmap: iodine → lutetium → actinium
Shares A university cyclotron network with shared regulatory files for new tracers, Lutetium-177 vipivotide tetraxetan, PSMA PET, Radioligand therapy (beta emitters).
- TrialVISION
Shares TheraP (ANZUP 1603), Lutetium-177 vipivotide tetraxetan, PSMA PET, Radioligand therapy (beta emitters).
cancers
technologies
drugs
ApprovedRadioligand therapy (beta)
Lutetium-177 vipivotide tetraxetan · Pluvicto